Hisamitsu Pharmaceutical Co Inc 2021 IR
The report introduces Hisamitsu Pharmaceutical Group's first Integrated Report, highlighting the launch of its 7th Mid-Term Management Policy, "Hisamitsu Transformation 2025 (HX2025)." The company aims to expand its business operations beyond patch products and accelerate global expansion, targeting an overseas sales ratio of 50% or higher by FY2025. In environmental efforts, the group achieved a 28% reduction in CO2 emissions by FY2020 compared to FY2013, moving closer to its 30% reduction target by FY2030 and aligning with the goal of net-zero emissions by 2050. Additionally, the company enhanced its corporate governance by increasing the percentage of Outside Directors on its Board to 40%.
Company: Hisamitsu Pharmaceutical Co Inc
Sector: Health Care
Country: Japan
Year: 2021
Type: IR
Pages: 22
Hisamitsu Pharmaceutical Co Inc
Integrated Report
The report introduces Hisamitsu Pharmaceutical Group's first Integrated Report, highlighting the launch of its 7th Mid-Term Management Policy, "Hisamitsu Transformation 2025 (HX2025)." The company aims to expand its business operations beyond patch products and accelerate global expansion, targeting an overseas sales ratio of 50% or higher by FY2025. In environmental efforts, the group achieved a 28% reduction in CO2 emissions by FY2020 compared to FY2013, moving closer to its 30% reduction target by FY2030 and aligning with the goal of net-zero emissions by 2050. Additionally, the company enhanced its corporate governance by increasing the percentage of Outside Directors on its Board to 40%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Mar 1, 2020 - Feb 28, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women in Management
Net Zero Target
Employees